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Summary We examined whether the increased expression of P-glycoprotein (P-gp) encoded by the human
multidrug resistance gene MDR] is related to the acquired multidrug resistance of lung cancer in vivo. We
estimated the chemosensitivity of lung cancer xenografts (LC-6, adenocarcinoma; Lu-24, small-cell cancer) by
calculation of relative tumour growth (T/C%, treated/control) in vivo, based on statistical significance
determined by the Mann-Whitney U test (P<0.01, one-sided). MDRJ gene expression levels were evaluated
by reverse transcription-polymerase chain reaction (RT-PCR) assay. P-gp production and P-gp localisation
were examined by Western blotting and by immunohistochemical analysis respectively. LC-6 and Lu-24 were
initially sensitive to both vincristine (VCR, 1.6 mg kg-': LC-6, 45%; Lu-24, 39%) and doxorubicin (DOX,
12 mg kg-': LC-6, 26%; Lu-24, 27%) in vivo. VCR-resistant variants (LC-6R, 66% and Lu-24R, 68%)
selected with VCR (0.4 mg kg-1, x 9) significantly acquired cross-resistance to DOX (LC-6R, 55% and Lu-
24R, 55% respectively). RT-PCR assay showed increased levels of MDR] expression in LC-6R and Lu-24R
with stable MDR] expression levels. P-gp expression levels were elevated, and the percentage of P-gp-positive
tumour cells increased in both LC-6R and Lu-24R. These results suggest that P-gp/MDRI overexpression is
related to acquired multidrug resistance in lung cancer in vivo.
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Lung cancer is generally treated by a combination of
therapeutic protocols using cisplatin, vinca alkaloids,
doxorubicin (DOX) and etoposide (VP-16) (Britran et al.,
1988; Williams, 1989; Hansen, 1992). However, the failure of
chemotherapy as a result of cellular drug resistance is still a
major problem in the treatment of lung cancer. Especially,
development of acquired drug resistance in tumours initially
sensitive to chemotherapy is a major issue in the treatment of
lung cancer patients.
Mechansims of multidrug resistance were analysed in
various human neoplastic cell lines resistant to anti-cancer
agents in vitro (Chen et al., 1986, 1990; Ueda et al., 1987).
Selection of cells resistant to lipophilic compounds (DOX,
vinca alkaloids, podophyllotoxins and colchicine) results in
the development of cross-resistance to other related drugs
(Fojo et al., 1985). This classical multidrug resistance
phenomenon is known to be related to the overexpression
of P-glycoprotein (P-gp) encoded by the human multidrug
resistance gene (MDR1) (Gros et al., 1986). Recently, atypical
multidrug resistance induced by overexpression of multidrug
resistance-associated protein (MRP) has been reported in
lung cancer cells in vitro (Cole et al., 1992; Versantvoort et
al., 1992; Zaman et al., 1993).
Our previous clinicopathological studies have not shown
intrinsic multidrug resistance in non-small-cell lung cancer
(NSCLC) to be related to P-gp/MDRJ (Abe et al., 1994a).
However, certain pulmonary adenocarcinomas revealed
significantly increased MDR1 expression. Many authors
have also reported drug resistance mechanisms associated
with P-gp in lung cancer (Lai et al., 1989; Volm et al., 1991;
Holzmayer et al., 1992). We did not find multidrug
resistance to be intrinsically related to MDR] overexpres-
sion in lung cancer xenografts (including LC-6 and Lu-24)
in vivo (Abe et al., 1994b). However, it has not been
clarified whether acquired multidrug resistance is related to
increased levels of MDR1 expression in human cancer cells
in vivo.
In this study, we selected VCR-resistant variants from
human NSCLC (LC-6R) and small-cell lung cancer (SCLC,
Lu-24R) xenografts in vivo, and evaluated whether these
VCR-resistant xenografts showed cross-resistance to DOX in
chemosensitivity tests in vivo. The expression levels of P-gp/
MDR] were also analysed before and after selection in these
xenografts. We also examined the gene expression levels of
miscellaneous factors associated with multidrug resistance
including MRP, topoisomerase IIcx (Topo Ila) and glu-
tathione-S-transferase-ir (GST-7t) in the xenografts. We
discuss here the hypothesis that acquired multidrug
resistance is induced by the increased expression of P-gp/
MDR1 in lung cancer in vivo.
Materials and methods
Human lung cancer xenografts
Two human xenografts (LC-6, NSCLC, adenocarcinoma; Lu-
24, SCLC, oat-cell type) were originally established at the
Central Institute for Experimental Animals (Kanagawa,
Japan) from primary lung cancer materials from patients
who had received no anti-cancer chemotherapy. The tumour
xenografts were maintained by serial subcutaneous trans-
plantation in nude mice (BALB/c-nu/nu, Clea Japan, Tokyo),
and used at 10-20 passages in this study. Xenograft
specimens obtained from mice sacrificed under deep
anaesthesia were frozen and stored at -80°C until
analysed. Tumour xenografts were also prepared for routine
histopathological values.
The drug-sensitive epidermoid carcinoma cell line, KB3-1,
and its resistant derivative, KB8-5, were cultured in
Dulbecco's modified Eagle's minimal essential medium
supplemented with 5% fetal bovine serum (FBS) at 37°C in
a fully humidified 95% air, 5% carbon dioxide atmosphere.
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Establishment of VCR-resistant xenografts in vivo
The human NSCLC (LC-6) and SCLC (Lu-24) xenografts
were sensitive to the maximum tolerated doses (MTDs) of
both VCR and DOX in vivo. We selected VCR-resistant
xenografts, LC-6R and Lu-24R, from LC-6 and Lu-24,
respectively, by serial passage in mice and by administration
of VCR (0.4 x 9 mg kg-') in vivo, according to our previous
report (Abe et al., 1993). No significant morphological
differences were noted between parental and VCR-resistant
xenografts.
In vivo chemosensitivity test
VCR (Shionogi, Osaka, Japan), DOX (Kyowa Hakkoh Kogyo,
Tokyo), cisplatin (Nihon Kayaku, Tokyo), mitomycin (Kyowa
Hakkoh Kogyo) and cyclosporin A (CysA, Sand, Toyko) were
purchased from the sources shown. All drugs were dissolved in
saline and used for in vivo chemosensitivity tests.
We performed in vivo chemosensitivity tests on the lung
cancer xenografts (LC-6, LC-6R, Lu-24 and Lu-24R)
according to the procedures reported previously (Inaba et
al., 1988, 1989). Six female mice (BALB/c-nu/nu, 6- 15 weeks
old) bearing xenografts (tumour volume: 100 -300 mm3) were
given the MTD of VCR (1.6 mg kg-1) or DOX
(12 mg kg-'). The tumour volume (V) was calculated by
the equation, V= 1/2 x A x B2, in which A and B are the
experimental measurements in mm of length and width
respectively. Growth of the tumour xenografts was measured
by the relative tumour volume (RV), which was expressed as
RV= V14/VO, in which V14 iS the tumour volume at day 14
and V0 is the initial tumour volume when the treatment was
started (day 0). The effects of the drugs were represented by
RV of the xenografts, and the T/C% values were defined as
the ratio of the RV of the treated tumour xenografts to
controls after drug administration. Animal experiments were
carried out in accordance with the guidelines established by
the Central Institute for Experimental Animals.
We examined the effects of prior inoculation with the P-gp
inhibitor CysA on the sensitivity to anti-cancer agents in the
xenografts in vivo, according to our previous report (Abe et
al., 1996). Nude mice bearing tumour xenografts were treated
with VCR (0.4 mg kg-') or DOX (12 mg kg-') 3 h after
intravenous administration of CysA (50 mg kg-'). VCR was
used at the low concentration of 0.4 mg kg in this study
because we had certified in advance that co-administration of
high doses of VCR (1.6 mg kg-') was fatal for the mice with
CysA.
Reverse transcription-polymerase chain reaction (RT-PCR)
assay
Total cellular RNA specimens were prepared from frozen
materials (Sambrook et al., 1989). The expression levels of
MDR] transcripts were determined by the modified RT-
PCR procedure described previously (Noonan et al., 1990),
using the following primers: sense, AAGCTTAGTACCAAA-
GAGGCTCTG, nucleotides 2041-2046; antisense, GGCTA-
GAAACATAGTGAAAAACAA, nucleotides 2260-2283
(Abe et al., 1994a). The primer sequences were derived from
exon 16 and exon 18, respectively, separated by introns to
prevent amplification of contaminating genomic DNA. We
avoided amplification of contaminating murine MDR gene
transcripts in the tumour xenografts by using the above
primers specific for the human MDR] gene (Abe et al.,
1994b). RT-PCR with these primers amplified a 243 bp
fragment of MDR] cDNA. We estimated MDRJ expression
level in comparison with that of the housekeeping gene J2-
microglobulin (,B2m).
Northern blot analyses
Total cellular RNA samples (20 ,ug) fractionated through
agarose gels were blotted onto nitrocellulose membranes
(Gene Screen Plus, New England Nuclear), and the blots
were hybridised with 32P-labelled MDR1 cDNA probe (kindly
supplied by Dr I Pastan, National Cancer Institute, Bethesda,
MD, USA). The level of MDRJ-specific transcript expression
(4.2 kb) was evaluated in comparison with that of the
housekeeping gene ,B-actin (2.2 kb).
Levels of expression of Topo Ila, GST-i and MRP genes
were also evaluated in thexenografts by Northern blotanalysis.
Complementary DNAs (Topo Ila, Dr T Ando; rat GST-i
cDNA, Dr A Sugioka through the Japanese Cancer Research
Resources Bank) were used. A human MRP cDNA was
prepared by PCR amplification ofthe fragment corresponding
to nucleotides 240-503 from KB8-5 cells (Ota et al., 1995). We
evaluated expression ofeach gene-specific transcript (Topo Ila,
4.6 kb; GST-n, 0.7 kb; MRP, 6.5 kb).
Western blotting
Solubilised samples were separated by sodium dodecyl
sulphate (SDS)-polyacrylamide gel electrophoresis (10%
polyacrylamide; 250 mM Tris, 250mM glycine, pH 8.3; 0.1%
SDS; for 42 min, at 200 V) according to the method of
Laemmli (Friedlander et al., 1989). The proteins were
electroblotted onto nitrocellulose membranes (Bio-Rad,
0.45 ,um pore size) in 48 mM Tris, 39 mM glycine, 0.0375%
SDS, 20% methanol at 0.8 mA cm2 for 1 h. The membranes
were probed with a monoclonal anti-human P-gp antibody
(C219, CIS Bio International; 0.2 Mg ml-', 1 h) after blocking
non-specific binding with 10% non-fat dried milk overnight
at 4°C. The blots were then incubated with biotinylated anti-
mouse IgG antibody (Vector Laboratories, Burlingame, CA,
USA), followed by incubation with streptavidin-peroxidase
complex (Vector). Peroxidase-labelled blots were then
examined by the enhanced chemiluminescence method
(Amersham).
Immunohistochemistry
P-gp-positive tumour cells were analysed immunohistochemi-
cally with anti-P-gp polyclonal antibody Ab-1 (Oncogene
Science) (Toth et al., 1994). Tumour sections were serially
incubated with Ab-1, peroxidase-conjugated F (ab')2 of
donkey anti-rabbit IgG (Amersham), rabbit monoclonal
peroxidase-antiperoxidase complex (Dako) and peroxidase-
conjugated F(ab')2 fragments. The products were visualised
with 3,3'-diaminobenzidine tetrahydrochloride.
Results
In vivo drug sensitivity
The growth rates of human lung cancer xenografts in the
chemosensitivity tests are shown with relative tumour volume
(Figures 1-3). Evaluation as 'sensitive' was defined based on
statistical significance determined by the Mann-Whitney U-
test (P<0.01, one-sided) (Abe et al., 1994b).
LC-6 was sensitive to the MTD of both VCR and DOX
(Figure la), and LC-6R selected in vivo by VCR was resistant
to VCR and acquired cross-resistance to DOX (Figure la).
Lu-24 was also initially sensitive to the MTD of both VCR
and DOX (Figure lb), and Lu-24R selected by VCR was
resistant to VCR and acquired cross-resistance to DOX
(Figure lb). Table I shows T/C% values of each xenograft in
vivo on day 14 after drug administration. The T/C% values
of LC-6 exposed to the MTD of VCR (45%) and DOX
(26%) were significantly lower than those (66% and 55%) of
LC-6R. The T/C% values of Lu-24 to the MTD of VCR
(39%) and DOX (27%) were also significantly lower than
those of Lu-24R (68% and 55%).
This acquired drug resistance in LC-6R was circumvented
by co-administration of CysA (Figure 2). The acquired drug
resistance to VCR of LC-6R was reversed by co-administra-
tion of CysA (T/C%: 90% to 38%), which when
administered alone showed no anti-cancer effect. Theacquired cross-resistance of LC-6R to DOX was also
circumvented by co-administration of CysA (T/C%: 55% to
15%). CysA did not apparently affect the growth of LC-6,
when it was administered with or without anti-cancer drugs
(data not shown).
The changes in responsiveness to non-P-gp-mediated anti-
cancer agents (cisplatin and mitomycin) were not significantly
different between LC-6 and LC-6R, while LC-6R showed a 3-
fold greater susceptibility to mitomycin C (Table I).
MDR1 expression
Northern blots showed no apparent MDR] expression in LC-
6, LC-6R, Lu-24 or Lu-24R xenografts. Semi-quantitative
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RT-PCR assay showed no MDRJ expression in LC-6 or Lu-
24 xenografts (Abe et al., 1994b). LC-6R and Lu-24R with
acquired cross-resistance, however, showed increased levels of
MDRI expression compared with the sensitive parent
xenografts LC-6 and Lu-24 (Figure 3). The xenografts LC-
6R and Lu-24R serially transplanted into nude mice (four
generations) without VCR showed no marked fluctuations in
the levels of MDRJ expression.
P-gp production
The VCR-resistant xenografts, LC-6R and Lu-24R, showed
increased production of P-gp protein by Western blotting in
comparison with the respective parent xenografts (LC-6 and
Lu-24 respectively; Figure 4). Immunohistochemical anlaysis
with anti-P-gp polyclonal antibody (Ab-1) also revealed
marked increases in the number of P-gp-positive tumour
cells in LC-6R and Lu-24R compared with their respective
parental xenografts (Figure 5), whereas LC-6 and Lu-24
xenografts showed no P-gp-positive tumour cells.
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Figure 1 (a) Growth rates of LC-6 and LC-6R in the in vivo
chemosensitivity test. (b) Growth rates of Lu-24 and Lu-24R in
the in vivo chemosensitivity test. Each group included six nude
mice bearing tumour xenografts. *, untreated control; 0,
maximum tolerated doses (MTDs) for vincristine (VCR)
treatment, 1.6mgkg-1; A, MTDs for doxorubicin (DOX)
treatment, 12mgkg-. Evaluation as 'sensitive' was strictly
defined, based on statistical significance determined by the
Mann-Whitney U-test (P<0.01, one-sided). Asterisks (*)
indicate significant differences between control and treated
groups.
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Figure 2 Growth rate of LC-6R in the in vivo chemosensitivity
test with cyclosporin A (CysA). Each group included six nude
mice bearing tumour xenografts. Evaluation as 'sensitive' was
strictly defined based on statistical significance determined by the
Mann-Whitney U-test (P<0.01, one-sided). Asterisks (*)
indicate a significant difference between control and treated
groups. *, untreated control; 0, VCR (0.4mgkg-1) treatment;
*, treated with only CysA, 50mgkg-1; *, VCR (0.4mgkg-')
treatment with CysA (50mgkg- ); El treated with DOX
(12mgkg-1) and CysA (50mgkg-1).,-"- P-gp-mediated MDR in lung cancer xenograft
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Figure 3 MDR] expression in the tumour xenografts determined
by reverse transcriptase-polymerase chain reaction (RT-PCR).
RT-PCR revealed a 243 bp fragment of MDR] cDNA. (a) Lane
1, KB8-5 xenograft; lane 2, KB3-1 xenograft; lane 3, LC-6; lanes
4-6, LC-6R serially passaged. (b) Lane 1, KB8-5 xenograft; lane
2, KB3-1 xenograft; lane 3, Lu-24; lanes 4-5, Lu-24R serially
passaged.
Table I In vivo chemosensitivity test [T/C% value at day 14 (U-test)]
Tumour Xenograft
LC-6 LC-6R Lu-24 Lu-24R
VCR 45+6 (+) 66+ 15 (-) 39+8 (+) 68+ 15 (-)
DOX 26+5 (+) 55+12 (-) 27+6 (+) 55+13 (-)
VCR*+CysA 38±8 (+)
DOX+CysA 15±3 (+)
CDDP 23+4 (+) 13+3 (+)
MMC 10 (+) 3+1 (+)
Relative tumour volume (RV) = V14/Vo, where VI4 iS tumour volume
at day 14 and V0 is the initial value at the beginning of treatment (day
0). T/C%, growth ratio ofthe relative volume ofthe treated xenografts
to controls (untreated) on day 14 of treatment (VCR, 1.6 mg kg 1,
*0.4 mg kg-1; DOX, 12 mg kg-1; CDDP, 7 mg kg-'; MMC,
1.7 mg kg '). U-test, significance of differences were estimated by the
Mann-Whitney U-test (P< 0.01, one-sided; +, significant; -, not
significant).
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Figure 4 P-gp production in the tumour xenografts. Western
blotting was performed with the anti-human P-gp monoclonal
antibody, C219. These VCR-selected multidrug-resistant xeno-
grafts (LC-6R and Lu-24R) showed enhanced production of P-gp.
Figure 5 Localisation of P-gp. Immunohistochemical analysis
was performed with anti-P-gp polyclonal antibody, Ab-1. The
multidrug-resistant xenografts (a, LC-6R; and b, Lu-24R)
contained P-gp positive cancer cells (arrow).
Topo IIa, GST-7r and MRP gene expression
No significant changes were observed in MRP, Topo IIx or
GST-7 gene expression between parent xenografts (LC-6 and
Lu-24) and their corresponding drug-resistant derivatives
(LC-6R and Lu-24R) by Northern blot analysis (data not
shown).
Discussion
Many studies using human tumour cell lines have revealed
that multidrug resistance mechanisms are correlated to the
overexpression of P-gp/MDRI in vitro (Chen et al., 1990;
Roninson, 1991). It has, however, not been clearly
demonstrated whether acquired multidrug resistance is
influenced by P-gp/MDRI overexpression in human cancers
in vivo (Starling et al., 1990).
The VCR-resistant variants (LC-6R and Lu-24R) selected
in vivo from drug-sensitive xenografts (LC-6 and Lu-24)
showed cross-resistance to DOX, and the drug resistance to
VCR and DOX of LC-6R was overcome by co-administra-
tion of the P-gp inhibitor, CysA. RT-PCR assay showed
increased levels of MDR] expression in LC-6R and Lu-24R,
whereas no marked changes were seen in the expression of
other miscellaneous drug resistance-related factors (Topo IIa,P-gp-modiated MDR in lung cancer xenograft
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GST-7 and MRP) (Zwelling et al., 1990; Nakagawa et al.,
1990; Cole et al., 1992). In LC-6R and Lu-24R, P-gp
expression levels were elevated and P-gp-positive tumour
cells increased. These results supported the hypothesis that
acquired multidrug resistance is induced by increased P-gp
protein/MDRJ gene expression in human lung cancer
xenografts.
Western blotting showed small amounts of P-gp in LC-6
and Lu-24, whereas a highly sensitive RT-PCR assay
revealed no MDRJ expression in these sensitive xenografts.
In this RT-PCR assay, we selected primers which were
specific for human MDR] and did not amplify the murine
mdr gene. Immunohistochemical analysis showed no P-gp-
positive tumour cells in these sensitive xenografts. Therefore,
the signals seen in LC-6 and Lu-24 might have included non-
specific reactions to murine P-gp-related molecules probably
in the stromal elements by Western blotting with murine
monoclonal anti-P-gp antibody, C219.
Several studies have shown that NSCLC with neuroendo-
crine properties expresses high levels of P-gp/MDRI (Lai et
al., 1989), while some authors revealed that the expression
levels ofP-gp/MDRI in lung cancer were not so high (Fojo et
al., 1987; Goldstein et al., 1989). On the other hand, we
reported enhanced MDRJ expression in a limited number of
pulmonary adenocarcinomas (Abe et al., 1994a). However, it
has not been demonstrated conclusively whether acquired
multidrug resistance in lung cancer is related to P-gp/MDRI
overexpression in vivo. The results presented here strongly
support the hypothesis that acquired multidrug resistance is
related to the increased expression of P-gp/MDRI in
pulmonary adenocarcinoma and small-cell lung carcinoma
in vivo.
The multidrug-resistant xenografts expressed MDR] at
lower levels than the in vitro multidrug-resistant carcinoma
line, KB8-5. It is very important to determine how MDR]
expression levels can induce the multidrug resistance of
tumour cells in lung cancer in vivo. Previously, we suggested
that in vivo sensitivity assays more accurately reflect drug
resistance as a result of low-level MDR] overexpression in
the human epidermoid carcinoma KB line (Abe et al., 1996).
Reduced levels of MDR] expression might be related to P-gp-
mediated multidrug resistance in vivo compared with that in
vitro.
It is difficult to determine whether the observed multidrug
resistance phenotype was caused by the clonal selection of
intrinsically P-gp-positive cancer cells or the activated
production of P-gp in resistant cancer cells (Chaudrey et
al., 1993; Chen et al., 1994; Brock et al., 1995). The
multidrug-resistant xenografts, LC-6R and Lu-24R, used in
this study showed stable MDRI expression during four serial
passages without exposure to VCR. Immunohistochemical
analysis revealed definite P-gp-positive cancer cells in
multidrug-resistant xenografts, whereas no P-gp-positive
tumour cells were detected in the parental xenografts. It is
impossible to conclude from these results whether the
observed multidrug resistance was owing to clonal selection
of P-gp-expressing cells or the activated production of P-gp.
Recently, the mechanism of atypical multidrug resistance
in lung cancer by MRP has been discussed (Cole et al., 1992).
Previously we demonstrated the clinical relevance of MRP
overexpression in the intrinsic multidrug resistance of
NSCLC, especially in pulmonary squamous cell carcinoma
(Ota et al., 1995). We are also currently engaged in studies to
determine the relevance of MRP in the acquired multidrug
resistance phenotype in pulmonary squamous cell carcinoma
xenografts.
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